达可替尼对比吉非替尼一线治疗表皮生长因子受体突变晚期非小细胞肺癌的成本-效果分析
洪望龙, 夏一淼, 苏广全, 张旭东, 方苹苹, 朱文涛, 郑淼淼, 马国强, 沈爱宗
Cost-effectiveness analysis of dacomitinib versus gefitinib in first line treatment of advanced non-small cell lung cancer with epidermal growth factor receptor mutation
HONG Wang-long, XIA Yi-miao, SU Guang-quan, ZHANG Xu-dong, FANG Ping-ping, ZHU Wen-tao, ZHENG Miao-miao, MA Guo-qiang, SHEN Ai-zong
中国医院药学杂志
.
2023, (8): 925
-930
.
DOI: 10.13286/j.1001-5213.2023.08.16
